Jim Tananbaum, Foresite Capital CEO (Business Wire)
June 29, 2021 10:25 AM EDTUpdated July 2, 01:36 PM
Financing
Deals

Gilead, Fore­site take an un­known pan­dem­ic an­tivi­ral pub­lic in $250M SPAC deal

Jason Mast

Editor

The SPAC boom has pro­duced some sur­pris­ing deals but gen­er­al­ly speak­ing, peo­ple fol­low­ing the in­dus­try have at least heard of the com­pa­nies go­ing pub­lic. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times